Azacitidine

BNF:

Immune System & Malignant Disease

Status:

Do Not Prescribe (DNP), Red

Decision Date:

August 2016

Comments

RED: 

• NICE TA827: Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy.  (Decision date - November 2022).

NHS England commissioned - to be used in line with NHSE commissioning intentions.

Do Not Prescribe (DNP): 

NICE TA399: for treating acute myeloid leukaemia with more than 30% bone marrow blasts.  (Decision date - August 2016).

Black Drug Classifications

• 6: Have NICE guidance that recommends they should not be used

search again